Breaking News

October 10, 2013
Programmed sickle cells for targeted delivery of cytotoxics to hypoxic tumors

as seen in the Journal of Controlled Release, 2013

journal of Controlled Release - 2013
JCR Cover Story .pdf
Adobe Acrobat document [279.8 KB]

Drug-loaded sickle cells programmed ex vivo for delayed hemolysis target hypoxic tumor microvessels and augment tumor drug delivery
as seen in the Journal of Controlled Release, 2013

Drug loaded SSRBCs
Drug loaded SSRBCs.pdf
Adobe Acrobat document [1.5 MB]

Staphylococcal entertotoxins of the enterotoxin gene cluster(egcSEs)induce nitrous oxide-and cytokine dependent tumor cell apoptosis in a broad panel of human tumor cells
as seen in Frontiers in Cellular and Infection Microbiology, August 13, 2013

egc NO superantigen
egc NO superantigen.pdf
Adobe Acrobat document [1.7 MB]


About Jenomic Research Institute

 

Jenomic is a biotech company devoted to developing novel drugs and drug vehicles for treatment of cancer. These efforts are supported by a raft of peer- reviewed publications and worldwide patents/patent applications.

 

The research team is led by David S. Terman, MD, an emeritus member of the American Society of Clinical Investigation (academia's physician-scientist honor society), former Professor  of Medicine, Microbiology and Immunology and Founding Director of Cancer Biology Program at Baylor College of Medicine. He is currently Adjunct Professor of Biochemistry and Molecular Biology at UAB in Birmingham. Dr. Terman is cited in Who's Who in America 2008-2013

As seen in the Monterey Herald

Cancer researcher David S. Terman stands among piles of research and patent paperwork in his home office in Pebble Beach on Friday. Terman runs the Jenomic Research Institute in Carmel. (DAVID ROYAL/The Herald)